Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA:688621)

SHA:688621 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	590.58	565.56	690.93	608.93	490.25	109.31
Short-Term Investments	-	20	-	-	-	-
Trading Asset Securities	80	30	30	13.11	157.6	-
Cash & Short-Term Investments	670.58	615.56	720.93	622.04	647.85	109.31
Cash Growth	-10.49%	-14.62%	15.90%	-3.98%	492.70%	42.90%
Accounts Receivable	831.1	774.96	555.83	362.73	239.2	112.78
Other Receivables	10.95	10.16	11.21	16.17	12	2.37
Receivables	842.04	785.12	567.04	378.9	251.21	115.15
Inventory	15.08	15.05	14.41	12.54	7.84	6.29
Prepaid Expenses	-	-	-	-	1.9	-
Other Current Assets	129.64	98.76	54.76	26.48	32.99	32.13
Total Current Assets	1,657	1,514	1,357	1,040	941.79	262.87
Property, Plant & Equipment	200.67	211.61	220.26	197.02	161.05	74.64
Long-Term Investments	55.94	115.69	100.75	94.75	40	-
Goodwill	26.06	26.06	26.06	26.06	26.06	26.06
Other Intangible Assets	4.74	5.41	5.39	4.2	3.32	4.04
Long-Term Deferred Tax Assets	72.19	64.04	38.93	16.69	5.03	2.65
Long-Term Deferred Charges	44.43	48.28	64.19	76.25	33.41	13.16
Other Long-Term Assets	73.87	1.73	50.31	8.78	31.99	1.43
Total Assets	2,135	1,987	1,863	1,464	1,243	384.86
Accounts Payable	34.78	7.31	7.83	22.13	12.52	9.55
Accrued Expenses	23.17	77.24	88.72	37.29	27.33	22.51
Short-Term Debt	486.13	309.39	383.93	201.17	138.01	23.5
Current Portion of Long-Term Debt	44.72	19.3	-	-	-	-
Current Portion of Leases	-	24.78	22.1	22.54	18.98	-
Current Income Taxes Payable	16.42	6.6	24.92	16.93	11.42	2.82
Current Unearned Revenue	393.23	321.43	220.83	205.85	199.85	128.29
Other Current Liabilities	14.97	12.51	12.88	12.27	9.72	5.27
Total Current Liabilities	1,013	778.56	761.21	518.19	417.83	191.94
Long-Term Debt	57.6	67.2	-	-	-	-
Long-Term Leases	30.86	35.12	40.62	33.84	49.72	-
Long-Term Unearned Revenue	3.27	2.52	3.59	2.83	5.46	-
Long-Term Deferred Tax Liabilities	0.08	1.25	0.35	0.24	-	-
Total Liabilities	1,105	884.65	805.76	555.1	473.01	191.94
Common Stock	112	112	112	80	80	60
Additional Paid-In Capital	375.86	375.86	474.17	499.85	499.85	52.66
Retained Earnings	642.35	612.78	453.85	317.09	182.1	76.44
Total Common Equity	1,030	1,101	1,040	896.93	761.95	189.1
Minority Interest	-0.21	2.01	17.25	11.67	7.69	3.81
Shareholders' Equity	1,030	1,103	1,057	908.6	769.64	192.92
Total Liabilities & Equity	2,135	1,987	1,863	1,464	1,243	384.86
Total Debt	619.32	455.79	446.65	257.55	206.71	23.5
Net Cash (Debt)	51.26	159.77	274.28	364.48	441.14	85.81
Net Cash Growth	-66.52%	-41.75%	-24.75%	-17.38%	414.12%	33.05%
Net Cash Per Share	0.46	1.42	2.45	3.26	4.50	1.02
Filing Date Shares Outstanding	109.28	112	112	112	112	84
Total Common Shares Outstanding	109.28	112	112	112	112	84
Working Capital	643.92	735.93	595.93	521.77	523.96	70.94
Book Value Per Share	9.43	9.83	9.29	8.01	6.80	2.25
Tangible Book Value	999.41	1,069	1,009	866.68	732.57	159.01
Tangible Book Value Per Share	9.15	9.55	9.01	7.74	6.54	1.89
Machinery	-	256.34	232.62	195.9	124.14	101.1
Construction In Progress	-	-	-	-	3.4	-
Order Backlog	-	3,273	-	-	-	-

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.